A drug that was developed over 50 years ago to tackle malaria is showing positive signs that it may also help cure COVID-19.
The results are claimed to be even more positive when the drug is combined with antibiotics, according to a new study.
In a press conference held this afternoon (Thursday 19th March), US President Donald Trump announced that the production of the drug has been ‘fast-tracked’ in the United States to treat people who have been diagnosed with COVID-19.
Hydroxychloroquine (sold under the brand name of ‘Plaquenil’) was ascertained to be effective in killing the deadly bug in laboratory experiments, Forbes reported, citing findings published on 9th March in the Clinical Infectious Diseases journal.
“We predict that the drug has a good potential to combat the disease,” the study’s authors wrote in a letter published in ‘Cell Discovery’ on Wednesday, according to the report.
French researchers have now also finished a largely successful clinical trial using the drug to treat patients who have caught COVID-19 according to a study published Wednesday.
A total of 36 patients were enrolled in the research which was led by Didier Raoult, an infectious disease expert from l’Institut Hospitalo-Universitaire in Marseille.
The test group was given 600 mg of Plaquenil each day.
The research team found that 50% of the treated group turned from positive to negative for the virus by the third day.
By day number six, that figure was up to 70%.
Of the 20 test patients, six who were treated with both Plaquenil and the antibiotic azithromycin showed effective results. Five tested negative at day three and all six of them tested negative at day six.
“Despite its small sample size, our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin,” the study concluded.
But it may still be some time until any treatment is widely used as more tests have to be carried out.
It is thought that the UK government is assessing the viability of using Hydroxychloroquine to treat patients and has banned companies from exporting the drug in a bid to shore up supplies in the UK, according to the DailyMail.
Find us in the new Google News App – search for ‘Emergency Services News’ and then click on the ‘star’ symbol to follow ESN.
Our social media group/community is open to both the public and emergency services personnel.
It is also a great place to share any emergency services related content (such as videos) which you have filmed.
If you have a story or video that you would like us to cover/share, then you can contact our team via email@example.com
We also cover stories which relate to the NHS, the armed forces and the security services.
Before you go...
We need your help. As former emergency services & armed forces personnel, we pride ourselves on bringing you important, fast-moving and breaking news stories which are free from the negative bias which is often directed at the emergency services by some sections of the mainstream media.
One of the reasons we started 'Emergency Services News' was because we became tired of reading badly informed stories about the emergency services which seemed only ever to highlight negative aspects of the job.
We want to be the unheard voice of the remarkable men and women who serve in the emergency services, NHS and armed forces. And with around 500k page views each month, we are getting there!
As income from ads, the mainstay source of income for most publishers, continues to decline; we need the help of our readers.
And remember, if you have a service, product or job vacancy that you would like to promote to our large readership, then you can buy advertising space in our articles.
You can support emergency services news from as little as £1. It only takes a minute. Every contribution, however big or small, is vital for our future.
Please help us to continue to highlight the life-saving work of the emergency services, NHS and armed forces by becoming a supporter.